Literature DB >> 15359108

Identification of antigen-specific IgG in sera from patients with chronic prostatitis.

Edward J Dunphy1, Jens C Eickhoff, Charles H Muller, Richard E Berger, Douglas G McNeel.   

Abstract

Antigen-specific vaccines are one of several molecularly targeted approaches under investigation as possible treatments for prostate cancer. Important to the development of vaccines is the identification of appropriate target antigens. We hypothesized that antigens of the prostate might be identified in patients with the chronic prostatitis/pelvic pain syndrome, a syndrome for which an autoimmune pathology has been proposed. Such antigens might represent naturally recognized target antigens of the prostate that could be investigated in the future as prostate tumor antigens. In this report, we used SEREX to identify proteins expressed in a prostate cDNA expression library recognized by IgG from the sera of patients with chronic prostatitis. Candidate proteins were evaluated using a panel of sera from 62 subjects with symptomatic prostatitis and 71 control male blood donors. We identified one protein that was recognized primarily in sera from subjects with prostatitis compared with controls. MAD-PRO-34, a nucleolar autoantigen, was recognized in 6/62 subjects and 0/71 controls (p = 0.00897). This protein had previously been identified as an autoantigen in patients with prostate cancer. In addition, the NY-CO-7 protein was recognized in 9/62 subjects and 3/71 controls (p = 0.0654). Two subjects had IgG specific for both the MAD-PRO-34 and NY-CO-7 gene products. Our results demonstrate that some patients with the chronic prostatitis/pelvic pain syndrome have autoantibodies to specific proteins. Proteins identified, and MAD-PRO-34 in particular, could be further investigated as potential prostate tumor antigens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15359108     DOI: 10.1023/B:JOCI.0000040920.96065.5a

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  36 in total

1.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Authors:  E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer.

Authors:  D G McNeel; L D Nguyen; B E Storer; R Vessella; P H Lange; M L Disis
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

Review 3.  Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.

Authors:  Y Kawakami; S A Rosenberg
Journal:  Int Rev Immunol       Date:  1997       Impact factor: 5.311

4.  Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Authors:  M G Sanda; D C Smith; L G Charles; C Hwang; K J Pienta; J Schlom; D Milenic; D Panicali; J E Montie
Journal:  Urology       Date:  1999-02       Impact factor: 2.649

Review 5.  Tumor vaccines for the management of prostate cancer.

Authors:  D G McNeel; M L Disis
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2000       Impact factor: 4.291

6.  Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS).

Authors:  G R D Batstone; A Doble; J S H Gaston
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

Review 7.  Serological analysis of human tumor antigens: molecular definition and implications.

Authors:  O Türeci; U Sahin; M Pfreundschuh
Journal:  Mol Med Today       Date:  1997-08

8.  In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate.

Authors:  T Bocker; A Bittinger; W Wieland; R Buettner; G Fauser; F Hofstaedter; J Rüschoff
Journal:  Mod Pathol       Date:  1995-04       Impact factor: 7.842

9.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

10.  Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer.

Authors:  A Fosså; R Siebert; H C Aasheim; G M Maelandsmo; A Berner; S D Fosså; E Paus; E B Smeland; G Gaudernack
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

View more
  17 in total

1.  Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.

Authors:  Douglas G McNeel; Heath A Smith; Jens C Eickhoff; Joshua M Lang; Mary Jane Staab; George Wilding; Glenn Liu
Journal:  Cancer Immunol Immunother       Date:  2011-12-31       Impact factor: 6.968

2.  Histopathological classification criteria of rat model of chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Xianjin Wang; Shan Zhong; Tianyuan Xu; Leilei Xia; Xiaohua Zhang; Zhaowei Zhu; Minguang Zhang; Zhoujun Shen
Journal:  Int Urol Nephrol       Date:  2014-11-20       Impact factor: 2.370

3.  Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.

Authors:  Daniel J Zabransky; Heath A Smith; Christopher J Thoburn; Marianna Zahurak; Daniel Keizman; Michael Carducci; Mario A Eisenberger; Douglas G McNeel; Charles G Drake; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2011-07-11       Impact factor: 4.104

4.  Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.

Authors:  Matthew D Morse; Douglas G McNeel
Journal:  Hum Immunol       Date:  2010-03-05       Impact factor: 2.850

5.  Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer.

Authors:  Brett B Maricque; Jens C Eickhoff; Douglas G McNeel
Journal:  Prostate       Date:  2011-02-01       Impact factor: 4.104

6.  An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans.

Authors:  Yafei Hou; Jason DeVoss; Vinh Dao; Serena Kwek; Jeffrey P Simko; Douglas G McNeel; Mark S Anderson; Lawrence Fong
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

Review 7.  Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy.

Authors:  Yuqian Liu; Junaid Wazir; Meng Tang; Rahat Ullah; Yueting Chen; Tingting Chen; Xiaohui Zhou
Journal:  Int Urol Nephrol       Date:  2020-11-16       Impact factor: 2.370

8.  A novel murine model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by immunization with a spermine binding protein (p25) peptide.

Authors:  Cengiz Z Altuntas; Firouz Daneshgari; Elias Veizi; Kenan Izgi; Fuat Bicer; Ahmet Ozer; Kerry O Grimberg; Bakytzhan Bakhautdin; Cagri Sakalar; Cemal Tasdemir; Vincent K Tuohy
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-01-23       Impact factor: 3.619

Review 9.  Etiologic theories of chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Michel A Pontari
Journal:  Curr Urol Rep       Date:  2007-07       Impact factor: 3.092

10.  Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.

Authors:  N E Annels; G R Simpson; M Denyer; S E McGrath; G Falgari; E Killick; R Eeles; J Stebbing; D Pchejetski; R Cutress; N Murray; A Michael; H Pandha
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.